Top-Rated StocksTop-RatedNASDAQ:EXAS Exact Sciences (EXAS) Stock Price, News & Analysis $45.19 +0.62 (+1.39%) (As of 07/8/2024 ET) Add Compare Share Share Today's Range$44.39▼$45.8750-Day Range$41.33▼$63.3552-Week Range$40.62▼$100.77Volume2.99 million shsAverage Volume2.82 million shsMarket Capitalization$8.34 billionP/E RatioN/ADividend YieldN/APrice Target$86.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Exact Sciences alerts: Email Address Exact Sciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.93 Rating ScoreUpside/Downside92.1% Upside$86.80 Price TargetShort InterestBearish5.12% of Shares Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment0.74Based on 9 Articles This WeekInsider TradingSelling Shares$90,105 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.15) to ($0.27) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.60 out of 5 starsMedical Sector68th out of 876 stocksMedical Laboratories Industry4th out of 17 stocks 4.5 Analyst's Opinion Consensus RatingExact Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 14 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageExact Sciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Exact Sciences' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.12% of the outstanding shares of Exact Sciences have been sold short.Short Interest Ratio / Days to CoverExact Sciences has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Exact Sciences has recently increased by 7.63%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldExact Sciences does not currently pay a dividend.Dividend GrowthExact Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExact Sciences has received a 74.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private genetic testing services", "Biochemical assay kits for colorectal cancer diagnostics", and "Biochemical assay kits for liver cancer diagnostics" products. See details.Environmental SustainabilityThe Environmental Impact score for Exact Sciences is -0.83. Previous Next 2.6 News and Social Media Coverage News SentimentExact Sciences has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Exact Sciences this week, compared to 7 articles on an average week.Search InterestOnly 12 people have searched for EXAS on MarketBeat in the last 30 days. This is a decrease of -54% compared to the previous 30 days.MarketBeat Follows10 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 11% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exact Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $90,105.00 in company stock.Percentage Held by InsidersOnly 1.36% of the stock of Exact Sciences is held by insiders.Percentage Held by Institutions88.82% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exact Sciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Exact Sciences are expected to grow in the coming year, from ($1.15) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exact Sciences is -34.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exact Sciences is -34.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExact Sciences has a P/B Ratio of 2.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Exact Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wealthpin ProThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.Click here to get all the information about it. About Exact Sciences Stock (NASDAQ:EXAS)Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Read More EXAS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EXAS Stock News HeadlinesJune 18, 2024 | marketbeat.comMyriad Genetics Sees Stock Surge with Hereditary Cancer Tests (EXAS)Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests includingJuly 8 at 8:30 AM | fool.comThis Cathie Wood Growth Stock Could Soar by 93%, According to Wall StreetJuly 9, 2024 | Wealthpin Pro (Ad)The Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.July 3, 2024 | americanbankingnews.comExact Sciences (NASDAQ:EXAS) Price Target Cut to $72.00 by Analysts at Evercore ISIJune 13, 2024 | investorplace.comJefferies Says Buy These 3 Stocks for More Than Double-Digit ReturnsJune 13, 2024 | fool.comIs It Time to Buy May's Worst-Performing Nasdaq Stocks?June 11, 2024 | seekingalpha.comExact Sciences: Still No Reason To OwnJune 3, 2024 | insidermonkey.comIs Exact Sciences Corporation (NASDAQ:EXAS) the Gene Therapy Stock with the Greatest Potential?July 9, 2024 | Wealthpin Pro (Ad)The Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.May 28, 2024 | businesswire.comExact Sciences to Participate in June Investor ConferencesMay 27, 2024 | finance.yahoo.comHedge Funds are Bullish on This Cancer StockMay 27, 2024 | investorplace.comBull Market Blastoff: 3 Stocks Targeting 56% to 91% ReturnsMay 24, 2024 | businesswire.comExact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®May 22, 2024 | businesswire.comCourt Dismisses Exact Sciences' ‘781 Patent Infringement Claim Against GeneoscopyMay 22, 2024 | businesswire.comExact Sciences Earns 2024 Great Place To Work® Certification™May 21, 2024 | bizjournals.comExact Sciences files second patent infringement case against competitorMay 21, 2024 | businesswire.comCourt Ruling Enables Exact Sciences to Proceed with Lawsuit against GeneoscopyMay 17, 2024 | investorplace.comWall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024See More Headlines Receive EXAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/09/2024Next Earnings (Estimated)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryBiotechnology Current SymbolNASDAQ:EXAS CUSIP30063P10 CIK1124140 Webwww.exactsciences.com Phone(608) 284-5700Fax608-284-5701Employees6,600Year Founded1995Price Target and Rating Average Stock Price Target$86.80 High Stock Price Target$121.00 Low Stock Price Target$70.00 Potential Upside/Downside+92.1%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($1.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-204,150,000.00 Net Margins-9.48% Pretax Margin-9.38% Return on Equity-7.12% Return on Assets-3.46% Debt Debt-to-Equity Ratio0.66 Current Ratio1.64 Quick Ratio1.45 Sales & Book Value Annual Sales$2.50 billion Price / Sales3.34 Cash Flow$0.02 per share Price / Cash Flow2,616.99 Book Value$17.39 per share Price / Book2.60Miscellaneous Outstanding Shares184,530,000Free Float182,020,000Market Cap$8.34 billion OptionableOptionable Beta1.22 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Kevin T. Conroy (Age 58)Chairman of The Board & CEO Comp: $1.54MMr. Jeffrey T. Elliott CFA (Age 46)EVP & CFO Comp: $518.13kMs. Sarah Condella (Age 43)Executive Vice President of Human Resources Comp: $742.76kMr. Everett V. Cunningham (Age 58)Chief Commercial Officer Comp: $1.34MDr. Jorge A. Garces Ph.D. (Age 52)Chief Science Officer Mr. Nassar NizamiChief Information OfficerMs. Megan JonesAssociate Manager of Investor RelationsMr. Tim CaprezChief Compliance Counsel & VPMr. James Herriott (Age 44)Senior VP, General Counsel & Secretary Mr. Vic ParkerHead of SalesMore ExecutivesKey CompetitorsCharles River Laboratories InternationalNYSE:CRLPRA Health SciencesNASDAQ:PRAHSyneos HealthNASDAQ:SYNHMedpaceNASDAQ:MEDPNational ResearchNASDAQ:NRCView All CompetitorsInsiders & InstitutionsThompson Investment Management Inc.Bought 33,487 shares on 7/8/2024Ownership: 0.105%DNB Asset Management ASBought 76,847 shares on 7/5/2024Ownership: 0.130%Moody National Bank Trust DivisionBought 741 shares on 7/3/2024Ownership: 0.005%GAMMA Investing LLCBought 444 shares on 7/2/2024Ownership: 0.001%EverSource Wealth Advisors LLCBought 340 shares on 6/11/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions EXAS Stock Analysis - Frequently Asked Questions How have EXAS shares performed this year? Exact Sciences' stock was trading at $73.98 on January 1st, 2024. Since then, EXAS stock has decreased by 38.9% and is now trading at $45.19. View the best growth stocks for 2024 here. How were Exact Sciences' earnings last quarter? Exact Sciences Co. (NASDAQ:EXAS) announced its quarterly earnings results on Wednesday, May, 8th. The medical research company reported ($0.50) earnings per share for the quarter, hitting the consensus estimate of ($0.50). The medical research company had revenue of $637.52 million for the quarter, compared to the consensus estimate of $624.95 million. Exact Sciences had a negative trailing twelve-month return on equity of 7.12% and a negative net margin of 9.48%. What is Kevin T. Conroy's approval rating as Exact Sciences' CEO? 328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend. Does Exact Sciences have any subsidiaries? Exact Sciences subsidiaries include these companies: Ashion Analytics, Thrive Earlier Detection Corporation, Base Genomics Limited, Paradigm Diagnostics Inc., Viomics Inc., Biomatrica Inc., Armune BioScience, and others. Who are Exact Sciences' major shareholders? Top institutional investors of Exact Sciences include DNB Asset Management AS (0.13%), Thompson Investment Management Inc. (0.11%), Moody National Bank Trust Division (0.01%) and GAMMA Investing LLC. Insiders that own company stock include Kevin T Conroy, Sarah Condella, Katherine S Zanotti, James Edward Doyle, Everett Cunningham, D Scott Coward, Daniel J Levangie, Jacob A Orville, Brian Baranick, Jeffrey Thomas Elliott and James Herriott. View institutional ownership trends. How do I buy shares of Exact Sciences? Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Exact Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL) and Block (SQ). This page (NASDAQ:EXAS) was last updated on 7/9/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredTop Hedge Funds Reveal A.I. Moonshot CoinsThe manager of top crypto hedge fund Pantera recently said every crypto company will soon be an artificial int...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
